The majority of deaths in COPD are from cardiovascular causes. Several large randomized controlled trials demonstrate that inhaled anticholinergic agents ipratropium and tiotropium increase the risk of serious cardiovascular events, including cardiovascular mortality. Tiotropium Respimat is associated with a statistically significant increased risk of mortality (RR 1.52; 95% CI 1.06 to 2.16) and cardiovascular death (RR 2.05; 95% CI 1.06 to 3.99) compared with placebo in a meta-analysis of clinical trials. In the largest study, the subgroup of patients with COPD in the Respimat group with known rhythm and cardiac disorders at baseline had an especially high risk for cardiac death (RR 8.6; 95% CI 1.1 to 67.2). Although there was no significantly increased risk of mortality (HR 0.89; 95% CI 0.79 to 1.02) or myocardial infarction (MI) (RR 0.73; 95% CI 0.53 to 1.00) with tiotropium handihaler in the Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) trial, the reported excess of angina (RR 1.44; 95% CI 0.91 to 2.26), imbalance in strokes related to ischaemia and rates of supraventricular tachyarrhythmias are consistent with the pro-ischemic and pro-arrhythmic effects. The subjects at greatest risk of cardiovascular death, such as those with a recent history of MI, unstable or life-threatening cardiac arrhythmias or hospitalisation with heart failure, were excluded from the UPLIFT trial. The Prevention of Exacerbations with Tiotropium in COPD trial showed an excess of serious coronary ischaemic events of angina, myocardial ischaemia and MI with the tiotropium Handihaler compared with salmeterol. The authors urge caution in prescribing inhaled anticholinergics for patients with preexisting arrhythmias or cardiac disorders.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the USA, and the majority of these deaths are from cardiovascular causes. 1 Since more than 80% of patients with COPD are cigarette smokers, they have a high prevalence of coronary artery disease. 2 In addition, patients with COPD are generally older and the prevalence of undetected arrhythmias is substantial. 2 A reduction in symptoms, primarily dyspnoea, and COPD exacerbations are the potential benefits of inhaled bronchodilators, including shortacting ipratropium bromide and long-acting tiotropium bromide, delivered as a dry powder (Spiriva Handihaler, Boehringer Ingelheim, Inc, Bracknell, UK) or via the new mist inhaler (Spiriva Respimat, Boehringer Ingelheim, Inc). These inhalers have not been demonstrated to alter the progressive decline in lung function or consistently improve survival in COPD. 3 Despite its quaternary ammonium structure which limits diffusion, tiotropium is systemically absorbed as demonstrated by more than 10-fold increased risk of acute urinary retention, especially in older men. 4 Ipratropium and tiotropium are actively transported through the bronchial epithelium using an organic cationic transporter (OCTN2), also present in the human heart. 5 There is preliminary evidence that ipratropium may induce myocardial injury via mitochondrial dysfunction. 6 7 Pro-arrhythmic effects Anticholinergic drugs suppress parasympathetic control of heart rate which is associated with an increased incidence of tachyarrhythmias and myocardial ischaemia. 8 Although tachyarrhythmias are often considered benign, they confer an increased risk of embolic strokes and sudden death in susceptible cardiac patients. 9 At the time of regulatory approval, tiotropium was known to be associated with mild decreased heart rate variability, 10 which is a known risk factor for cardiac mortality and sudden cardiac death. 11 The Lung Health Study investigators reported a RR for hospitalisations due to supraventricular tachycardia of 4.5 (95% CI 0.97 to 20.8) associated with use of short-acting inhaled ipratropium versus placebo. 12 The accurate prevalence of tachyarrhythmias in randomised controlled trials (RCTs) of tiotropium has not been reliably ascertained because 24 h Holter ECG monitoring was conducted in only a few small studies, 13 14 and resting 12-lead ECGs performed during clinic visits rarely detect them. However, despite these limitations, an increased risk of arrhythmias associated with tiotropium has been consistently reported in many clinical trials of both formulations.
3 15e17 Furthermore, the large RCTs of ipratropium and tiotropium have shown a trend towards an increased risk of arrhythmias in comparison with placebo and other bronchodilator drugs. For example, the Understanding Potential Long-Term Impact of Tiotropium on Lung Function Trial (UPLIFT), a large 4-year study of the efficacy of the Spiriva Handihaler, reported relative risks of tachyarrhythmias of 3.70 (95% CI 0.79 to 17.4) and atrial tachycardias of 7.39 (95% CI 0.92 to 59) reported as adverse events. 17 In a recent analysis of three placebo-controlled RCTs from the indacaterol development programme of patients who completed 24 h Holter ECG monitoring those randomised to tiotropium Handihaler had a RR of newly occurring, non-sustained ventricular tachycardia of 1.84 (95% CI 0.89 to 3.43). 18 
Serious ischaemic cardiovascular effects
In 2002 the Lung Health Survey reported that ipratropium increased the risk of cardiovascular death compared with placebo (RR 2.57; 95% CI 1.08 to 6.15; p¼0.03). 12 In 2008 a metaanalysis of 17 RCTs of inhaled anticholinergics demonstrated a statistically significant increased risk (RR 1.60; 95% CI 1.22 to 2.10) for the combined endpoint of stroke, myocardial infarction (MI) and cardiovascular deaths (including sudden death) with inhaled anticholinergic inhalers; the RR for all-cause mortality was 1.29 (95% CI 1.00 to 1.65). 19 In 2011, a meta-analysis of five RCTs reported a statistically significant increased risk of all-cause mortality (RR 1.52; 95% CI 1.06 to 2.16) and cardiovascular death (RR 2.05; 95% CI 1.06 to 3.99) with tiotropium Respimat inhaler compared with placebo. 20 In this meta-analysis there was a doseeresponse effect on all-cause mortality, which was primarily due to an excess of cardiac deaths. It was estimated that one excess death would be expected for every 124 patients treated with 5 mg of tiotropium administered via the Respimat for 1 year.
In the largest Respimat study, patients with COPD in the Respimat group with known rhythm and cardiac disorders at baseline had an especially high risk for cardiac death (RR 8.6; 95% CI 1.1 to 67.2 in those with rhythm disorders at baseline; RR 4.03; 95% CI 1.15 to 14.13 in those with cardiac disorders at baseline). This risk was not statistically significant in patients with baseline use of cardiovascular medications (RR 1.62; 95% CI 0.53 to 4.95) or a history of coronary artery disease (RR 1.08; 95% CI 0.15 to 7.67). 17 This observation is particularly important when the findings of no significant risk of mortality (HR 0.89; 95% CI 0.79 to 1.02) or MI (RR 0.73; 95% CI 0.53 to 1.00) with tiotropium in the UPLIFT trial are considered. The UPLIFT trial excluded patients with COPD with unstable arrhythmias, a history of heart failure, or a heart attack within the previous 6 months. Furthermore, the UPLIFT trial did not monitor adverse events for over 40% of participants who terminated treatment. Sudden deaths were categorised as 'general deaths' and not included as cardiovascular deaths. 17 These design limitations reduced the ability of the trial to ascertain ischaemic and arrhythmic events. It is notable that the RR for serious adverse events for angina reported as a serious adverse event was 1.44 (95% CI 0.91 to 2.26) with tiotropium in UPLIFT. 3 The other significant recent study is the Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD) trial 21 22 Patients with MI or congestive heart failure within a year, severe cardiovascular disease, those with cardiac arrhythmias or those with moderate to severe renal failure (creatinine clearance >50 ml) were excluded from the trial. Although the trial was not adequately powered for individual cardiovascular endpoints an excess of angina pectoris (9/3707 vs 5/3669), myocardial ischaemia (11/3707 vs 6/3669) and MI events (20/ 3707 vs 13/3669) was noted with tiotropium Handihaler compared with salmeterol. This risk occurred despite a significant reduction in severe exacerbations of COPD with tiotropium.
In contrast to the sponsor's previous analysis of 29 placebocontrolled trials which reported an excess of stroke with tiotropium, 17 UPLIFT reported no significant difference in the composite endpoint of number of patients with stroke with tiotropium (82 vs 80). 16 This composite endpoint of all-cause stroke may have masked an imbalance in the potential risk of ischaemic stroke 16 In another pooled analysis of three placebocontrolled RCTs, inhaled tiotropium Handihaler was the only COPD drug (compared with formoterol or indacaterol) associated with a statistically significant increased risk of cardiovascular and cerebrovascular adverse events compared with placebo (RR 1.67; 95% CI 1.02 to 2.73). 18 The findings above should be viewed in the context of the overall results of arrhythmias and ischaemic cardiovascular events and mortality occurring in long-term trials of inhaled anticholinergics (>24 weeks), as shown in online table 1, identified through systematic reviews and reviews of regulatory documents. 17 19 20 A significant increase in overall mortality with tiotropium Respimat is largely due to cardiovascular deaths. The tiotropium Handihaler and Respimat studies are consistently characterised by an increase in supraventricular arrhythmias and myocardial ischaemia manifest as angina in several large trials, including UPLIFT and the POET-COPD trial.
None of these trials were designed to measure cardiovascular outcomes and several long-term trials such as UPLIFT and POET-COPD excluded participants with cardiovascular risk. Incompleteness of reporting and incomplete ascertainment bias all the estimates towards the null. The absence of formal statistical significance in underpowered safety studies should not be construed as proof of safety. 23 
CONCLUSIONS
The inhaled anticholinergic agents ipratropium and tiotropium have the potential to increase the risk of serious cardiovascular events, including mortality, when used in the treatment of COPD. These findings have regulatory, scientific and clinical implications. Spiriva Respimat has not received regulatory approval in the USA because of an increased risk of mortality in clinical trials, but continues to be marketed in more than 55 countries. The Medicines and Healthcare Products Regulatory Agency in the UK has required a warning about the use of tiotropium Respimat in patients with cardiac rhythm disorders but not for other anticholinergics. 24 Although an excess of angina and tachyarrythmias are noted on the current US label for the Spiriva Handihaler, 16 and tachyarrhythmias are listed in the summary of product characteristics (European 6 label), 15 neither label has any warnings or restriction regarding use of Handihaler in patients with cardiovascular disease. Thus the labels do not accurately capture or convey the extent and seriousness of pro-arrhythmic and pro-ischaemic risks associated with inhaled anticholinergic medications (Spiriva, Atrovent and Combivent, Boehringer Ingelheim, Inc).
Adequately powered cardiovascular safety trials of anticholinergic inhalers (short and long acting) are needed. Such trials should include objective tests of baseline cardiovascular disease; comprehensive ECG Holter monitoring at baseline and during follow-up; and complete ascertainment of the outcome measures of ischaemic cardiovascular events such as myocardial ischaemia, MI, ischaemic stroke and cardiovascular death (including sudden death) and all-cause mortality. This trial should include an enriched population of participants with a cardiac history to determine cardiovascular effects. There should be thorough objective monitoring for cardiovascular symptoms and consultation with cardiac specialists when necessary. We urge caution in prescribing inhaled anticholinergics for patients with pre-existing arrhythmias or cardiac disease. For each patient, the benefit of dyspnoea relief and reduction in COPD exacerbations should be weighed against the potential risks of serious cardiovascular adverse effects. 
